Vésale Bioscience, a Namur, Belgium-based company which specializes company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, received a €1.8M grant from European Innovation Council.
The company intends to use the funds to develop a phage therapy diagnostic platform for global fight against multidrug-resistant infections.
Led by CEO Gunther Vanwezer, and chief scientific officer Dr Johan Quintens, Vésale Bioscience is an R&D company specializing in phage therapy, particularly in alternative solutions to antibiotics and the development of treatments for multi-resistant infections. The therapy represents an innovative and promising solution in the fight against multi-drug resistant infections. Its technology consists of a phagogram with artificial intelligence, which allows decentralized diagnosis and personalized therapy. It guarantees a reactivity in a very short time (three hours instead of three days). The company also has a phage library of 96 references. Since 2020, Vésale Bioscience has been collaborating with the Belgian army in the framework of a ‘Triple Helix’ agreement between industry, the federal government and academia, a first for an R&D project on phage therapy.
Vésale Bioscience’s selected project, PhageDiag, is a fast and user-friendly diagnostic technology, or phagogram, for personalized phage therapy. It is the first automated in vitrodiagnostic tool that enables a quick determination of suitable bacteriophages for treating a particular bacterial infection. PhageDiag consists of a basic test kit (a disposable well plate with reagents), a high-performance luminometer and a dedicated software that offers the best matching phage combination to treat the patient, using artificial intelligence.
Founded in 2018, Vésale Bioscience is based in Namur, Belgium and employs about 20 staff. Its team includes world-renowned experts, who have helped achieve major advances in the development of research and production process design.
FinSMEs
17/01/2023